Anser RZB
Use
The Anser RZB test is designed for monitoring risankizumab (RZB) and antibodies-to-RZB (ATR) levels. This test helps in achieving optimal therapeutic responses by guiding dosage adjustments based on serum drug concentrations.
Special Instructions
Using homogeneous mobility shift assay (HMSA) methods, this test measures both the drug and antibody levels effectively in serum without drug interference issues common in other assay methods.
Limitations
Anser RZB is a laboratory-developed test which has not been approved by the FDA. It follows CLIA guidelines for its clinical and analytical validation but does not have WHO standards due to the nature of RZB.
Methodology
Immunoassay (HMSA)
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.0 mL
Minimum Volume
0.5 mL for Peds
Container
Serum Separator Tube or Red-Top Tube
Storage Instructions
Transport ambient or with a cold pack. Do not freeze.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |